Pneumonectomy; a risky type of resection in non-small cell lung cancer: survival and mortality analysis

Serkan Yazgan1*, Soner Gursoy1, Ahmet Ucvet1, Ozgur Samancilar1, Ahmet Emin Erbaycu2, Mehmet Unal1, Tarik Yagci1

1Department of Thoracic Surgery, University of Health Sciences, Dr. Suat Seren Chest Diseases and Surgery Medical Practice and Research Center, Izmir, Turkey
2Department of Chest Diseases, University of Health Sciences, Dr. Suat Seren Chest Diseases and Surgery Medical Practice and Research Center, Izmir, Turkey

ABSTRACT

Background: This study aims to evaluate the mortality and survival rates of patients undergoing pneumonectomy due to primary non-small cell lung cancer (NSCLC) and to identify the factors which affect these variables.

Materials and Methods: This retrospective single center cohort study included a total of 250 patients who underwent pneumonectomy due to NSCLC between January 2007 and July 2015. 30- and 90-day mortality rates and survival rates of the patients were analyzed. The factors which affected survival and mortality were evaluated.

Results: The mean age was 59 (range: 35 to 77) years. The median survival was 48.1 months (95% C. I. 30.6 – 65.6 months) and five-year survival rate was 45.6%. The 30- and 90-day mortality rates were 6.4% and 7.6%, respectively. Age, nodal disease, and complete resection were factors to affect the survival (p = 0.002, p = 0.0001 and p = 0.017, respectively). Age was also effective on 30- and 90-day mortality (p = 0.004, RR: 3.3 and p = 0.006, RR: 2.5, respectively). The early rethoracotomy rate was 5.6% (n = 14) and the postoperative mortality rate in these patients was 28.6% (n = 4).

Conclusions: Although implementation of pneumonectomy due to lung cancer seems fearful, the present study found lower survival rates only depending on advanced age and N2 disease. The high levels of 30- and 90-day mortality and the increased mortality after early rethoracotomy was associated with advanced age and comorbidity. In terms of postoperative mortality, the selection of eligible patients is important in elderly patients who are candidates of pneumonectomy due to lung cancer.

Key Words: non-small cell lung cancer, pneumonectomy, survival rate, early mortality
Introduction

Prior to 1930, pneumonectomy was fatal due to bleeding, the lack of durable bronchial closure methods and antisepsis. Later, lobectomy were shown to have similar efficacy along with less morbidity, leading to gradually reduced indications for pneumonectomy [1]. However, pneumonectomy may be still inevitable due to anatomical and technical reasons. As it is associated with higher morbidity and mortality, compared to other lung resections, the effect of pneumonectomy on long-term survival is still controversial.

In the present study, it was aimed to evaluate the mortality and survival rates of patients who underwent pneumonectomy due to primary non-small cell lung cancer (NSCLC) and to identify the factors affecting these variables.

Materials and Methods

A written informed consent was obtained from each patient. The study was approved by the institutional study board and was conducted in accordance with the principles of the Declaration of Helsinki.

This retrospective study included a total of 250 patients who had pneumonectomy due to NSCLC between January 2007 and July 2015. Patients who had completion pneumonectomy, pneumonectomy due to an indication other than NSCLC were excluded. Data including age, histology, lymph node metastasis, T status, neoadjuvant therapy, adjuvant therapy, and the state of complete and incomplete resection at the surgical margin during post-resection histopathological examinations were obtained from hospital records operation reports, patient charts, and national survival database. All patients were analyzed in terms of 30- and 90-day mortality rates and survival. The survival time was calculated as the duration between the days of operation and death. The factors affecting survival and mortality were assessed statistically. Cardiac disease, hypertension, diabetes mellitus and previous tuberculosis were recorded as comorbidities.

Preoperative assessment included posteroanterior chest x-ray, thoracic, and upper abdominal computed tomography (CT), bronchoscopy, positron emission tomography, cranial magnetic resonance imaging or CT, pulmonary function tests (PFT) and blood gas analysis as a standard procedure. For eligible patients, transthoracic fine-needle aspiration biopsy, and mediastinal lymph node staging with endobronchial ultrasonography and/or mediastinoscopy were performed. The patients with the forced expiratory volume in 1 second (FEV1) level >2 l or 70% as measured by PFT underwent pneumonectomy prior to any advanced respiratory assessment. For the patients with PFT levels considered insufficient; quantitative perfusion scintigraphy, maximal oxygen consumption (VO2peak) and stair climbing tests were performed. Respiratory physiotherapy was applied as guided by physiotherapists in the postoperative period. Smoking patients were ensured to quit smoking at least one week before the operation.

Prior to thoracotomy, all patients were administered antibiotic and pulmonary embolism prophylaxis. During the operation, anesthesiologists conducted double-lumen intubation, arterial and central venous pressure monitorization and epidural analgesia as a standard procedure. The serratus anterior muscle was preserved and posterolateral thoracotomy was performed. To achieve a complete resection, additional procedures such as intrapericardial procedures or chest wall resection as well as extended pneumonectomy were performed when necessary. For bronchial closure, mostly stapler was used upon surgeon’s choice. Each patient underwent systematic mediastinal and hilar lymph node dissection. The surgical margins were assessed by a pathologist using the frozen-section procedure. At the end of the operation, a thoracic drain was inserted. Extubation was ensured in the operating room as far as possible and the patients were kept under supervision for 24 to 48 hours in the intensive care unit. The amount of fluid drainage was followed and the thoracic drain was removed within the first 72 hours. The discharged patients were followed in the outpatient setting. All complications and mortalities were recorded.

Statistical Analysis

Data were collected from hospital database, operational reports, patient charts and national mortality database. Excel software (Microsoft Corp, Seattle, WA) was used to analyze the data. The means and standard deviations of the continuous variables, and number and percent of categorical variables were given by using descriptive statistics. Statistical analysis was performed using the SPSS 16.0 software program (SPSS Inc., Chicago, IL,
USA). All cumulative survival curves were estimated using the Kaplan–Meier method, and differences between the groups were evaluated by the log-rank test. The overall survival (OS) was considered as the time from the date of initial surgery to the date of death from any cause or the date of the last follow-up. Variables with a P-value less than 0.1 were selected for further multivariable analysis. Multivariable analysis for OS was performed to identify the prognostic factors using the Cox proportional hazard model.

**Results**

During the study period, there were a total of 1,267 patients who had lobectomy and pneumonectomy due to primary NSCLC in our clinic, and 1,017 (80.3%) of these cases were lobectomy and 250 (19.7%) were pneumonectomy. The lobectomy / pneumonectomy rate was 4.1. The mean age of the pneumonectomy patients was 59 (range: 35 to 77) years. There were 32 patients (12.8%) aged under 50 years, 88 patients (35.2%) aged between 50 and 60 years, 98 patients (39.2%) aged between 60 and 70 years, and 32 patients (12.8%) aged above 70 years. The majority of the patients were males (94.8%), and the most common histopathological type was squamous-cell carcinomas (72.8%). In terms of T status, most of the patients were T2 with 168 patients (67.2%). In addition, 55 patients (22%) had comorbidities. A total of 72 patients (28.8%) were operated following neoadjuvant chemotherapy, while postoperative 50 patients (20%) were found to have N2 disease. Also, 106 patients (42.4%) received adjuvant chemotherapy (Table 1). Adjuvant therapy was given to 27 patients (37.5%) who received neoadjuvant therapy. Most of the patients (70%) had left pneumonectomy and R0 resection was implemented at a rate of 97.2%.

| Table 1. Demographics and the characteristics of the study population and the survival data. |
|---------------------------------|---------|-----------------|-----------------|--------|
|                                | n      | Rate (%)        | 5 year survival (%) | Median survival (months) | P      |
| Total                          | 250    | 45.6            | 48.1              | 0.06   |
| Gender                         |        |                 |                  |        |
| Female                         | 13     | 5.2             | 19.5              | 20.1   | 0.06   |
| Male                           | 237    | 94.8            | 46.1              | 56.8   |        |
| Age                            |        |                 |                  |        |
| < 50                           | 32     | 12.8            | 58.6              | NA     | 0.002  |
| 50 ≤ age < 60                  | 88     | 35.2            | 51.2              | 61     |        |
| 60 ≤ age < 70                  | 98     | 39.2            | 43.7              | 42.4   |        |
| ≥ 70                           | 32     | 12.8            | 24.1              | 20.7   |        |
| Comorbidity                    |        |                 |                  |        |
| Yes                            | 55     | 22              | 41.9              | 56.8   | 0.49   |
| No                             | 195    | 78              | 46.7              | 42.4   |        |
| Neoadjuvant                    |        |                 |                  |        |
| Yes                            | 72     | 28.8            | 39.1              | 33.2   | 0.24   |
| No                             | 178    | 71.2            | 48.4              | 59.3   |        |
| Adjuvant                       |        |                 |                  |        |
| Yes                            | 106    | 42.4            | 49.5              | 59.7   | 0.07   |
| No                             | 144    | 57.6            | 42.9              | 39.6   |        |
| Histology type                 |        |                 |                  |        |
| Squamous                       | 182    | 72.8            | 48.2              | 58.7   | 0.09   |
| Nonsquamous                    | 68     | 27.2            | 38.4              | 30.5   |        |
| Tumor size                     |        |                 |                  |        |
| ≤ 3 cm                         | 82     | 32.8            | 40.5              | 30.5   | 0.06   |
| 3-7 cm                         | 143    | 57.2            | 44                | 48.1   |        |
| ≥ 7 cm                         | 25     | 10              | 68.8              | NA     |        |
| T stage                        |        |                 |                  |        |
| T0/1                           | 12     | 4.8             | 54                | NA     | 0.67   |
| T2                             | 168    | 67.2            | 45.2              | 49.7   |        |
| T3/4                           | 70     | 28              | 47.4              | 31.3   |        |
| N stage                        |        |                 |                  |        |
| N0/1                           | 200    | 80              | 50.1              | 60.3   | 0.001  |
| N2                             | 50     | 20              | 28                | 22.4   |        |
| Side                           |        |                 |                  |        |
| Left                           | 175    | 70              | 44.3              | 40.3   | 0.81   |
| Right                          | 75     | 30              | 48.8              | 58.7   |        |
| Resection                      |        |                 |                  |        |
| Complete                       | 243    | 97.2            | 46.1              | 49.7   | 0.02   |
| Incomplete                     | 7      | 2.8             | 28.6              | 4.1    |        |

NA: Not available; Bold values: P < .05
The mean follow-up was 36.2 ± 28.6 (range: 0.1 to 104.9) months, and the median survival was 48.1 months (95% C.I. 30.6 – 65.6 months). The five-year overall survival rate was 56.6% (Figure 1).

The survival rates were lower in female patients (p = 0.06), non-squamous-cell carcinoma patients (p = 0.092), and those who did not receive adjuvant chemotherapy (p = 0.07); however, it did not show any statistical significance (Table 1). The difference in age groups (p = 0.002), detection of N2 disease (p = 0.001) and incomplete resection (p = 0.017) were found to significantly affect the survival rates. The five-year survival rate was 58.6% under 50 years of age, compared to 24.1% at the age of 70 and above (Figure 2).

The five-year survival rate was 28%, and median survival was 22.4 months for N2 disease (Figure 3) and 28.6% and 4.1 months, respectively for incomplete resection (Figure 4). The five-year survival was lower among patients receiving neoadjuvant therapy compared to those who did not (39.1% vs. 48.4%, p = 0.24).

During follow-up, disease progression was occurred in 80 patients (32%); 13 of them (16.2%) were local recurrence, 18 (22.5%) were both local recurrence and distant metastasis, and 49 (61.2%) were distant metastasis. Early rethoracotomy was performed in 14
patients (5.6%) within the postoperative 30 days; after left pneumonectomy in 10 and right pneumonectomy in four patients. The reasons for early rethoracotomy were bronchopleural fistula in seven patients, bleeding in six patients, and chylothorax in one patient. Six of the seven patients with fistula were cases with right pneumonectomy. Postoperative mortality occurred in four patients from early rethoracotomy group; two were due to bronchopleural fistula and two due to bleeding. The postoperative mortality rate after early rethoracotomy was 28.6% (4/14 patients).

The 30- and 90-day mortality rates were 6.4% and 7.6%, respectively. The review of national database revealed that 126 patients (50.4%) died and 70 of these patients (28%) died due to progression of NSCLC. Of the patients, 114 (45.6%) are alive and disease-free. The other 10 patients (4%) alive despite local recurrence or metastasis.

The Cox’s regression analysis revealed statistically significant results for the analyses related to age groups, nodal disease, complete resection, histology, and adjuvant therapy (Table 2).

The most influential factor in 30- and 90-day mortality was found to be age (p = 0.004 and p = 0.006, respectively) (Table 3), and the odds ratio from the logistic regression analysis was 3.3 (p = 0.001) and 2.5 (p = 0.003), respectively. The 30- and 90-day mortality in the presence of comorbidity was 12.7% and 14.5%, respectively (p = 0.05 and p = 0.04, respectively).

### Discussion

Pneumonectomy has a higher operative risk compared to more limited resections and there are different opinions about its effect on long-term survival [1]. Nevertheless, this procedure is still performed due to anatomic or technical reasons. Pneumonectomy accounts for 10 to 35% of all lung resections [2,3]. The tumors for which pneumonectomy is needed are often larger and centrally located.
localized. Therefore, mediastinal lymph node metastasis are more common, and performing preoperative invasive staging is important for these patients.

The former studies report that the five-year overall survival rate is 21 to 41% [1,2,4,5]. In this study, we found median survival to be 48.1 months and five-year overall survival rate to be 45.6% in 250 pneumonectomy cases. These rates were 48.8% and 44.3% for right and left pneumonectomy, respectively. The long-term overall survival rate for pneumonectomy was slightly higher in our study, than previously reported. This can be attributed to the fact that advanced stage diseases are detected more and surgical treatment is not performed on such patients in recent years as we have used advanced imaging techniques and invasive staging methods. This is also supported by our patient group 80% of which consisted of N0 and N1 patients. Similar two series reported higher postoperative N2 disease rate as 26% and 41% [1,6]. Of our patients with detected N2 disease, 60% had a squamous-cell carcinoma and 32% had an adenocarcinoma. This finding is contrary to some reports indicating that squamous cell carcinomas have a lower biological potential for mediastinal lymph node metastasis [6].

According to the tumor size in patients with postoperative N2 disease, it was found that 34% of the patients had a tumor <3 cm, whereas 66% had a tumor >3 cm in diameters. This finding suggests that there is a link between increased tumor size and N2 detection. The subgroup analyses of our study revealed that advanced age, incomplete resection and N2 disease have a significantly negative effect on long-term survival, whereas sex, histology, tumor size, the side of the operation, presence of comorbidity and adjuvant or neoadjuvant therapy did not have any statistically significant effect. The age group analysis showed that survival rates were higher in the younger group. The five-year survival rate was 58.6% among patients under 50 years of age compared to 24.1% among patients the age of 70 and above. It is known that R0 resection is one of the most important variables affecting survival. The rate of patients with detected R1 is reported to vary between 12% and 10.6% in various series [5,7]. This rate was 2.8% in our study and only one patient received neoadjuvant therapy. In our study, the five-year survival rate was 28.6% in R1 group compared to 46.1% in R0 group (p = 0.017). This can be considered as a proof that microresidual disease is an indicator of poor prognosis.

Currently, the lobectomy/pneumonectomy rate is on the increase due to sleeve lobectomies that are performed as an alternative to pneumonectomy. The lobectomy/pneumonectomy rate was four in our series. There are series with such rate of 4.9 in consistent with our study [5]; however, we believe that this rate should be further higher. A study that investigated the chronological changes in lung cancer surgery during the past 41 years found that the lobectomy/pneumonectomy rate has increased to 15.6 from 5 [4]. Similarly, the sublobar resections has increased (3% vs. 38%), whereas the pneumonectomy rate has significantly reduced (16% vs. 4%).

It is important for surgeons to reduce the higher morbidity and mortality risk of pneumonectomy and identify the causes of early postoperative deaths. Our study demonstrated that 19.7% of the resections performed due to NSCLC were pneumonectomy, and the 30- and 90-day overall mortality rates were 6.4% and 7.6%, respectively. These values are in strong agreement with the results of studies conducted at some experienced centers, which were published within the past five years (Table 4). However, early mortality rates are expected to be even lower upon developing technology and novel surgical methods and more modernized intensive care units. In the literature, an analysis including 1949 and 2002 reports showed that post-pneumonectomy 30-day overall mortality varied between 3.1 and 17% [8], whereas this rate has been reported to vary between 3.2% and 8.3% for the past five years [9-12].

<p>| Table 4. Mortality rates of pneumonectomy for nonsmall cell lung cancer in different series. |
|----------------------------------|---------------|-------------|-------------|</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>n</th>
<th>30 days mortality-n (%)</th>
<th>90 days mortality-n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powell et al.10</td>
<td>2013</td>
<td>1121</td>
<td>78 (7%)</td>
</tr>
<tr>
<td>Pezzi et al.12</td>
<td>2014</td>
<td>7949</td>
<td>663 (8.3%)</td>
</tr>
<tr>
<td>Frick et al.9</td>
<td>2015</td>
<td>186</td>
<td>6 (3.2%)</td>
</tr>
<tr>
<td>Pricopi et al.11</td>
<td>2015</td>
<td>1805</td>
<td>110 (6.1%)</td>
</tr>
<tr>
<td>Our study</td>
<td>2017</td>
<td>250</td>
<td>16 (6.4%)</td>
</tr>
</tbody>
</table>

Furthermore, the present study also showed that advanced age had an adverse effect on mortality. The analysis of 30-day mortality revealed that there was no patient aged under 50, and 14 of 16 patients died.
were above the age of 60. Post-pneumonectomy 30-
day mortality was significantly higher among elderly
patients, compared to other resections [1,3]. Therefore, it
is obvious that a more serious care is required for elderly
patients. A study examining post-pneumonectomy
prognosis among elderly lung cancer patients reported
a significantly higher level of pneumonia and bronchial
fistula in the older patient group compared to the younger
patient group [13]. In addition, the aforementioned
study showed a significantly higher rate of operation-
related mortality in the older patient group.

Nonetheless, the role of neoadjuvant therapy is still
questionable. Some series report lower postoperative
mortality following neoadjuvant therapy [2], while
others report higher early postoperative mortality
[14] or higher mortality only in right pneumonectomy
[15]. Our study showed a statistically significant
difference in early mortality following neoadjuvant
therapy. However, contrary to many other studies,
we found 30-day mortality lower among patients that
received neoadjuvant therapy compared to those who
had pneumonectomy without any preoperative therapy
(2.8% vs. 7.9%, p = 0.16). This difference is likely to
result from the fact that the patients to whom surgery
was recommended following neoadjuvant therapy were
selected among patients with best conditional status.
A meta-analysis carried out between 1990 and 2010
analyzed 27 studies and found the mean 30-day mortality
rate for pneumonectomy following neoadjuvant therapy
to be 7% [16]. The study emphasized higher 30- and 90-
day mortality in right pneumonectomies compared to left
pneumonectomies. Although there was no significant
difference in the morbidity rates, some authors reported
that early mortality was significantly higher in right
pneumonectomies [9]. Similarly, we also observed higher
early mortality rates in right pneumonectomies (9.3% vs.
5.1%, p = 0.26). The common reason for high mortality
in right pneumonectomy include more bronchopleural
fistula rate at the right side, the postoperative cough not
being adequately effective due to the lengthiness and
position of the left main bronchus, and the functional
predominance of the ablated lung [2,11]. Among our
study population, 10 of 14 patients undergoing early
rethoracotomy following pneumonectomy had right
pneumonectomy. Additionally, six of seven patients
undergoing rethoracotomy due to bronchopleural fistula
also had right pneumonectomy. This indicates that right
pneumonectomy is associated with higher morbidity
and mortality.

In conclusion, based on the findings from our single-
center study, we suggest that preoperative evaluation
should be made more meticulously and invasive staging
should be performed to exclude N2 disease in all patients
especially in advanced-age indicated for pneumonectomy.
As early mortality following neoadjuvant therapy
seems low, pneumonectomy can be performed safely
in these patients. In addition, it should be kept in mind
that pneumonectomy is likely to be curative when not
avoidable, when performed by experienced professionals
following a thorough assessment.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect
to the authorship and/or publication of this article.

Funding

The authors received no financial support.

References

1. Riquet M, Mordant P, Pricopi C, Lebras A, Foucault C, Dujon A
et al. A rewiev of 250 ten year survivors after pneumonectomy
45: 876-81.


complications after lung resection for non-small cell lung
cancer in elderly patients at a single institution in China. J

H, Saji H. Chronological changes in lung cancer surgery in a
single Japanese institution. Onco Targets and Therapy 2017;
10: 1459-64.

5. Thorsteinsson H, Alexandersson A, Oskarsdottir GN,
Skuladottir R, Isaksson HJ, Jonsson S et al. Resection rate and
outcome of pulmonary resections for non - small - cell lung

Kashii T et al. Results of pneumonectomy for non - small cell


